北陆药业: 公司章程

Group 1 - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][3] - The registered capital of the company is RMB 491,855,896 [3] - The company was approved by the China Securities Regulatory Commission to issue 17 million shares of ordinary stock to the public in 2009 [2][3] Group 2 - The company's business scope includes the production and sale of large-volume injections, small-volume injections, tablets, granules, and raw materials [4][5] - The company aims to leverage its technological advantages and high-tech talent resources to provide high-quality pharmaceutical products and services [4] Group 3 - The company has a share structure consisting of ordinary shares, with a total of 491,855,896 shares issued [8] - The shares are issued at a par value of RMB 1 per share [8] Group 4 - The company’s shareholders have the right to receive dividends and participate in decision-making processes at the shareholders' meetings [12][13] - Shareholders holding more than 5% of the shares are subject to specific trading restrictions [10][11] Group 5 - The company’s board of directors is responsible for major decisions, and shareholders have the right to request the convening of shareholder meetings under certain conditions [20][23] - The company must disclose information regarding significant transactions and decisions to ensure transparency [42][43]